CVS Health earns NCQA utilization management accreditation
CVS Health’s pharmacy benefits manager CVS Caremark has been accredited by the National Committee for Quality Assurance in utilization management.
The NCQA utilization management accreditation is earned through a quality assessment program focused on protecting consumers and improving customer service. Its standards recognize applicants with open access networks that can use customized structures to meet purchaser needs while improving service quality.
“At CVS Caremark, we are pleased to maintain our NCQA Utilization Management Accreditation, which we’ve held continuously for the past several years,” CVS Health COO Jonathan Roberts said. “This accreditation affirms that our program provides high quality service and care to our PBM clients and their members as we strive to ensure that members access clinically appropriate and cost effective therapies to help improve health outcomes and lower costs.”
CVS Caremark’s utilization management program is designed to encourage appropriate and effective medication use. The company said that it identifies optimal drug use and promotes drug benefit plans that are cost-effective by using evidence-based drug information, as well as published guidelines, consensus statements and standards of medical practice.
“Achieving utilization management accreditation from NCQA demonstrates that CVS Health has the systems, process and personnel in place to conduct utilization management in accordance with the strictest quality standards,” NCQA president Margaret O’Kane said.
The accreditation process involves an evaluation that is conducted by a team of physicians and managed care experts, whose findings are then analyzed by an independent oversight committee of physicians, which then assigns an accreditation status based on an organization’s performance against standards.
Teva Canada intros generic Concerta
Teva Canada has launched its generic Concerta (methylphenidate hydrochloride). The extended-release tablet is indicated to treat attention deficit hyperactivity disorder in patients ages 6 years and older.
“We’ve heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to Concerta that works in the same way and at the same time,” Teva Canada senior director of commercial management David Boughner said. “We’re pleased to offer patients ACT Methylphenidate ER as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration. In addition, the pharmacokinetic parameters mimic the concentration-time release profile of Concerta.”
ADHD is the most common neurodevelopmental disorder, affecting roughly 1-in-20 children, according to Portico, Canada’s mental health and addiction network.
Teva Canada’s generic Concerta will be available in 18-, 27-, 36- and 54-mg tablets. The once-daily drug had a Canadian market size of roughly $175 million for the 12 months ended January 2018, according to IQVIA data.
Sun Pharma’s Ilumya gets FDA approval
The Food and Drug Administration has approved Sun Pharma’s Ilumya (tildrakizumab-asmn). The biologic drug is indicated to treat moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” Sun Pharma president and CEO, North America, Abhay Gandhi said. “We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis.”
Ilumya is meant to be administered in a 100-mg dose every 12 weeks after two intial doses four weeks apart.